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Cyclosporine-associated thrombotic microangiopathy in renal to transplantation, such as uveitis [5], rheumatoid arthri-
allografts. tis [8], and psoriasis [2], indicates a possible causal rela-
Background. The association between cyclosporine (CsA) tionship between this drug and the microangiopathicand thrombotic microangiopathy (TMA) in renal allografts is
process. It is noteworthy that only a minority of thewell documented. However, predisposing factors and therapy
patients with CsA-associated TMA have the full clinicalguidelines are not adequately characterized.
Methods. We reviewed 188 patients with kidney or kidney- picture of hemolytic uremic syndrome [9] and that the
pancreas transplants who were treated between January 1994 diagnosis is frequently not apparent before the renal
and December 1996 with prednisone, CsA, or tacrolimus, and
biopsy is performed.azathioprine or mycophenolate. We analyzed 50 patients who
Diagnostic histopathological changes in the acutehad graft biopsies: 26 with TMA and 24 with no TMA, as well
as 19 patients with well-functioning grafts who never required phase of CsA-associated TMA have been described in
biopsy. detail in glomeruli and arterioles [10]. Fibrin thrombi,
Results. TMA was observed in 26 of 188 renal graft recipi- focal necrosis, and mesangiolysis of the glomerular tuft,ents (14%). TMA was confined to the allograft kidney without
sometimes accompanied by cellular crescents, are associ-any systemic evidence in 24 of the 26 patients. At the time of
ated with occlusive concentric cellular proliferation ofthe diagnosis of TMA, 24 of the patients were on CsA, with
19 on the microemulsion form. Conversely, 5 of 18 control the arterioles, which also frequently show fibrin thrombi
patients with no graft dysfunction were on the microemulsion [3, 11]. Although vascular rejection generally affects
form of CsA (P 5 0.0026). Graft loss was seen in 8 of 26 patients
muscular arteries, it is occasionally accompanied by fi-with TMA. Conversion from CsA to tacrolimus resulted in
brin thrombi in arterioles and glomerular capillaries [12].a one-year salvage of graft function in 13 of 16 (81%) patients.
Conclusions. TMA was the cause of renal graft dysfunction The chronic changes of CsA-associated TMA include
in 14% of renal graft recipients and was associated with the hyalinization of the arterioles, duplication of the glomer-
use of the microemulsion form of CsA. Systemic signs of TMA ular basement membrane, segmental and global glomer-were rare, underscoring the importance of the graft biopsy in
ulosclerosis, interstitial fibrosis, and tubular atrophy [3,making the diagnosis. The most successful strategy was switch-
10, 13–15].ing from CsA to tacrolimus, with good graft function in 81%
of the recipients one year after the TMA episode. Experience with CsA-associated TMA in renal allo-
graft recipients is generally anecdotal, and detailed de-
scriptions of clinical behavior, therapeutic options, and
Since the advent of cyclosporine (CsA), thrombotic outcomes are few. Our experience with a relatively large
microangiopathy (TMA) has been observed as a side number of TMA cases in kidney and kidney–pancreas
effect of this form of therapy in bone marrow graft recipi- transplant patients during a three-year period (1994
ents [1] and in patients treated with solid organ trans- through 1996) prompted this retrospective review. The
plantation, including kidney [2–7]. The occurrence of aim of this study was to identify possible contributing
TMA in patients receiving CsA for conditions not related factors to CsA-associated TMA, and to investigate thera-
peutic modifications that result in better graft survival
Key words: thrombosis, transplantation, kidney-pancreas transplanta- in these patients.
tion, rejection therapy, renal biopsy.
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Organ Transplantation Program during a three-year pe- brin thrombi were observed in arterioles or glomerular
capillaries [3, 11, 17]. Although vascular changes diag-riod, between January 1, 1994, and December 31, 1996.
One hundred forty-nine patients were transplanted with nostic of severe acute rejection predominate in muscular
vessels, arterioles and glomeruli may become involvedkidney only. Thirty-eight patients simultaneously re-
ceived kidney and pancreas allografts, and one patient in severe or accelerated rejection [18, 19]. Acute rejec-
tion was graded using the Banff criteria [16, 20]. Chronichad sequential kidney and pancreas grafts. During the
three-year period, 19 patients never had renal graft dys- transplant nephropathy was graded based on the severity
of interstitial fibrosis and tubular atrophy [16, 20].function and were not biopsied. The other 169 recipients
had a total of 396 renal graft biopsies for the diagnosis
Statistical analysisof renal graft dysfunction, and the number of biopsies per
patient varied from one to seven. Renal graft dysfunction Statistical comparisons were made using chi-square
analysis with Yates’ correction or Student’s unpairedwas defined as a rise in serum creatinine (SCr) of 0.5 mg/
dl or greater above baseline. t-test where appropriate, using GraphPad Prism 2.01
(StatMate) for Windows 95 (GraphPad Software Inc.,
Therapy San Diego, CA, USA).
Therapy during the three-year period included in this
study consisted of CsA or tacrolimus (Prograf; Fujisawa-
RESULTS
USA, Deerfield, IL, USA); azathioprine, or mycopheno-
Clinical datalate mofetil (CellCept; Roche, Nutley, NJ, USA), and
prednisone. CsA was initially started at 10 mg/kg dose The clinical data of the 188 recipients are shown in
Table 1. All patients included in this study had negativeand was later titrated according to trough blood levels
and maintenance dose in the range of 5 to 8 mg/kg. serology for hepatitis C. TMA was observed in 26 of the
188 renal allograft recipients (that is, 14%) and in 26 ofBlood levels were measured by high-performance liquid
chromatography (HPLC). CsA was used in two forms: the total of 169 patients who had a renal graft biopsy
(that is, 15%). Of the 162 renal graft recipients who didSandimmunet (Novartis, Summit, NJ, USA) and the
microemulsion form, Neoralt (Novartis). When Neoral not have TMA, 116 (72%) had functioning grafts with
a mean SCr of 2.43 6 0.8 mg/dl at the end of the three-became available, new patients were placed on this form
of therapy, and some of the patients who had been on year study period.
Patients with TMA did not differ significantly withthe older preparation (Sandimmune) were converted,
depending on the primary physician’s preference. respect to age, sex, race, living-related vs. cadaveric do-
nor status, and human lymphocyte antigen match statusWe routinely used a dihydropyridine calcium channel
blocker for the treatment of post-transplantation hyper- from the recipients with no TMA. Although more male
and African American patients were transplanted duringtension, occasionally with the addition of a loop diuretic.
We did not use prophylactic induction therapy with ei- the index period, TMA appeared to be more frequent
in female and in Caucasian recipients; however, the dif-ther antithymocyte globulin or murine anti-CD3 anti-
bodies (OKT3; Orthoclone, West Orange, NJ, USA). ference was not statistically significant. Furthermore, cy-
tomegalovirus (CMV) mismatch was not increased inHowever, these agents were used when renal graft dys-
function was shown by kidney biopsy to be due to an the TMA patients, as shown in Table 1. TMA was ob-
served in 7 of the 39 recipients (18%) of simultaneousacute rejection of a moderate or severe grade according
to the Banff classification [16]. kidney and pancreas grafts, and in 19 of 149 patients
(13%) who received a kidney-only graft. The difference
Renal allograft biopsies is not statistically significant.
The allograft was from a living-related donor in 27All biopsies were studied by light microscopy. At our
institution, unless clinically indicated, immunohisto- cases: (a) Eight of the living-related graft recipients expe-
rienced no renal graft dysfunction and represented 42%chemistry and electron microscopy are not performed
routinely in renal graft biopsies. For this study, all slides of the 19 patients in the group of patients with well-
functioning grafts who did not necessitate a biopsy. (b)were reviewed by the same pathologist (S.M.S.). Findings
in glomeruli, tubules, interstitium, arterioles, and muscu- Eleven living-related kidney recipients had episodes of
renal graft dysfunction other than TMA. (c) Eight living-lar arteries were graded using a semiquantitative method:
absent (0), mild (1), moderate (11), and severe related graft recipients had TMA, corresponding to 31%
of the 26 patients with TMA. The differences are not(111). We routinely obtained a total of 10 slides per
transplant biopsy, and stained five with hematoxylin and statistically significant and are consistent with the inter-
pretation that living-related status did not confer protec-eosin, three with periodic acid-Schiff, and two with tri-
chrome. tion against renal graft dysfunction.
The incidence of post-transplantation urinary tract in-Thrombotic microangiopathy was diagnosed when fi-
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Table 1. Renal graft recipients: Clinical data for patients with and without thrombotic microangiopathy (TMA)
Patients with TMA Patients without TMA Total
number of number of number of
patients % patients % patients %
26 14 162 86 188 100
Recipients’ sex
Female 15 58 66 41 81 43
Male 11 42 96 59 107 57
Age Average 32.5 years 61.9 38.2 years 61.6 34.8 years 62.1
Race
Caucasian 15 58 74 46 89 47
African American 11 42 83 51 94 50
Other — — 5 3 5 3
Native renal disease
Diabetic nephropathy 8 31 45 28 53 28
Glomerulonephritis (various) 5 19 30 19 35 19
Allograft
Kidney-only transplant 19 73 130 80 149 79
Kidney-pancreas transplant 7 27 32 20 39 21
Multiple renal transplants 2 8 16 5 18 10
Living related donor 8 31 19 12 27 14
Cadaveric renal donor 18 69 143 88 161 86
Mismatch AAB1D average 3.9 61.0 3.961.2 3.9 60.9
Acute tubular necrosis 3 12 60 37 63 34
CMV mismatch 4 15 33 20 37 20
Differences between the groups are not statistically significant.
fection episodes was similar in patients with TMA (5 of Findings in patients with thrombotic microangiopathy
26 patients; 19%) and with no TMA (35 of 162; 22%). The diagnosis of TMA was made by graft biopsy in
For our study, three groups of patients were selected. all the 26 patients. At the time point of the diagnosis of
(a) Patients with TMA. All 26 patients who had a TMA, 2 patients were on tacrolimus and 24 patients
diagnosis of TMA by kidney allograft biopsy during the were on CsA. Of the 24 patients on CsA, 5 were on
index period were included in this study. These 26 pa- Sandimmune, and 19 were on the microemulsion form,
Neoral. Ten patients had started with Neoral dosagetients had a total of 79 biopsies for renal graft dysfunc-
form, and an additional nine patients were convertedtion, that is, a rise in SCr of 0.5 mg/dl or greater above
from Sandimmune to Neoral. The difference betweenbaseline. A total of 30 renal graft biopsies was obtained
the number of TMA patients on Neoral and of patientsfor renal graft dysfunction at time points prior to the
with no renal graft dysfunction on Neoral is statisticallydiagnosis of TMA; 38 renal graft biopsies showed TMA,
significant (x2 5 9.09, P 5 0.0026) and is shown inand 11 biopsies were obtained for renal graft dysfunction
Figure 1. No significant difference was observed betweenat time points after the diagnosis of TMA had been
the number of patients on Neoral when TMA patientsmade.
are compared with patients with renal graft dysfunction(b) Biopsy control patients. The biopsy control group
of other causes. All but two patients were on a long-included 24 recipients who had several graft biopsies for
acting dihydropyridine calcium channel blocker (nifedi-episodes of renal graft dysfunction (a rise in SCr of 0.5 pine or amlodipine).mg/dl or greater above baseline) secondary to causes
Of the 26 patients, only 2 had systemic signs of TMA,
different from TMA. Patients in this group were selected that is, thrombocytopenia, evidence of intravascular he-
from a total of 169 patients who had a kidney biopsy for molysis in peripheral smear, and elevated lactate dehy-
renal graft dysfunction when one of the biopsies was drogenase (LDH) levels. These two patients were on
obtained within one week of the biopsy from a patient Neoral when the diagnosis of TMA was made. They
with TMA, and the non-TMA patient had a comparable were treated with plasmapheresis and high-dose steroids,
degree of renal graft dysfunction. These 24 patients had followed by successful resolution and preservation of
a total of 67 renal biopsies. the graft in one. In the other patient, despite extensive
(c) No-biopsy control patients. The no-dysfunction pheresis, the microangiopathic process did not abate un-
control group included 19 recipients who did not have til after transplant nephrectomy.
episodes of renal graft dysfunction and who never re- The time point of the diagnosis of TMA was highly
variable, between 4 and 2190 days post-transplantation.quired a renal graft biopsy.
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The other statistically significant findings in biopsies with
TMA, shown in Table 2, included occlusive concentric
edematous proliferation of the cells of the arteriolar
walls in 34 of 38 (89%) and epithelial crescents in 9 of
38 biopsies (24%). Cellular crescents involved less than
10% of the glomeruli in most biopsies. Conversely,
biopsies from the patient with three different episodes
of TMA showed crescents in 38 and 30% of the glomeruli
in the biopsies obtained during the second and third
episodes, respectively. Immunoglobulins were not de-
tected by immunofluorescent histochemistry. It is note-
worthy that only three of the 38 biopsies with TMA
showed moderate or severe rejection. (b) In the 30 biop-
sies taken for renal graft dysfunction episodes prior to
the diagnosis of TMA, moderate or severe rejection was
present in nine (30%). Isometric vacuolization of the
cytoplasm of the tubular epithelium, considered a sign
of acute CsA toxicity, was observed in four (13%). Eigh-
teen of the biopsies performed for renal graft dysfunction
episodes occurring prior to the diagnosis of TMA were
obtained during the first 90 post-transplantation days.
Interstitial fibrosis and tubular atrophy were not ob-
Fig. 1. At the time point of the diagnosis of thrombotic microangiopa- served, and moderate or severe rejection was present in
thy (TMA), the use of immunophilins was as follows: (1) Of 26 renal nine (50%). (c) Biopsies taken for renal graft dysfunctiongraft recipients with TMA, 2 patients were on tacrolimus (h) and 24
occurring at time points after the episode of TMA showon cyclosporine (CsA), of which 5 were on Sandimmunet ( ) and
19 were on Neoralt ( ). (2) Of 24 renal graft recipients with graft that there is cellular proliferation of the arteriolar wall
dysfunction not resulting from TMA, 5 were on tacrolimus and 19 were in 8 of 11 (73%), chronic transplant nephropathy in 8on CsA, 2 of which were on Sandimmune and 17 were on Neoral. (3)
of 11 (73%), and arteriolar hyalinization in 6 of 11 (55%).Of the 19 renal graft recipients who did not have episodes of graft
dysfunction, 1 was on tacrolimus and 18 were on CsA, 13 of whom Isometric vacuolization of the tubular epithelium was
were on Sandimmune and 5 were on Neoral. The difference between not seen in any of these biopsies.column 1 and 3 is statistically significant (chi-square 5 9.09, P 5 0.0026).
Upon the diagnosis of TMA, one of the following
three therapeutic interventions was implemented: con-
version of CsA to tacrolimus, reduction of CsA or tacroli-
mus dose, discontinuation of CsA or tacrolimus. ThereFourteen patients (12 of 14 on Neoral) were in their first
post-transplantation year, and 12 patients (7 of 12 had were no predetermined protocol interventions; in each
case, the decision to change therapy was made by thebeen converted to Neoral) were beyond that time point.
A single episode of TMA was seen in 24 recipients; one nephrologist responsible for the care of the patient.
The treatment strategies selected after the diagnosispatient had two episodes and another three, separated
by time periods of over 60 days. None of the TMA of TMA are shown for all our patients in Table 3.
In 16 patients, CsA was replaced by tacrolimus (pa-patients had been transplanted for previous hemolytic
uremic syndrome. tients one to 16; Table 3). The formulation was 0.5 to
1.0 mg/kg, to maintain a blood level of 5 to 12 ng/ml; aThe 79 biopsies obtained from the 26 patients with
TMA are subdivided as follows: 30 biopsies from 17 level of 10 to 20 ng/ml is generally considered to be the
therapeutic range for this drug, especially during thepatients, taken during episodes of renal graft dysfunction
(SCr between 1.4 and 9.8 mg/dl, average 3.2 mg/dl) prior first year after transplantation. Only 3 of the 16 patients
(shown as 14 to 16 on Table 3) had to be placed onto the onset of TMA; 38 biopsies diagnostic of TMA
from 26 patients (SCr between 1.9 and 6.8 mg/dl, average dialysis 15 to 180 days after the TMA diagnosis. Renal
grafts were functioning well within one year of the TMA4.3 mg/dl); and 11 biopsies from 11 patients taken for
episodes of renal graft dysfunction (SCr between 2.4 and episode in 13 of 16 (81%) patients in whom CsA was
replaced by tacrolimus. Furthermore, 11 patients had9.4 mg/dl, average 5.6 mg/dl) occurring after the diagno-
sis of TMA. The following findings were observed in functioning grafts upon their most recent check-up, be-
tween 1.7- and 6.2-years post-transplantation, with a SCrthese biopsies: (a) The diagnosis of TMA was made
when fibrin thrombi, as illustrated in Figure 2, were ob- of between 1.1 and 2.9 mg/dl (average 2.02 6 0.17).
A further eight patients, 17 through 24 in Table 3,served. The thrombi were localized in arterioles in 29 of
38 biopsies (76%) and/or in glomeruli in 20 of 38 (53%). were on CsA when the diagnosis of TMA was made on
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Fig. 2. The lumen of the arteriole in the upper half of the center of the field is occluded by a fuchsinophilic mass (fibrin thrombus). In contrast,
the arteriole in the lower portion of the field contains red blood cells. The interstitium is edematous (3600, trichrome).
Table 2. Renal graft biopsies
Recipients with TMA
Pre-TMA TMA Post-TMA
(N 5 30) (N 5 38) (N 5 11)
N % N % N %
Recipients
without TMA
N 5 67
N %
Fibrin thrombi 0 0 38a 100 0 0 0 0
Cellular crescent 0 0 9a 24 0 0 0 0
Arteriolar wall proliferation 6 20 34a 89 8 73 26 39
Arteriolar hyalinization 7 23 14 37 6 55 8 12
Tubular CsA toxicity 4 13 1 3 0 0 5 7
Acute tubular necrosis 3 10 1 3 1 9 17 25
Rejection, mild 8 27 6 16 4 36 11 16
Rejection, moderate or severe 9 30 3 8 8 73 13 19
Chronic Tx nephropathy 10 33 18 47 8 73 31 46
Comment: All biopsies were performed for graft dysfunction, that is, when there was a rise in SCr of 0.5 mg/dl or greater above baseline.
Abbreviations are: TMA, thrombotic microangiopathy; Tx, transplantation.
a Result is significant when compared to biopsy from patients with no TMA (P , 0.0001)
the renal graft biopsy. The CsA was discontinued in other patient had been switched to tacrolimus because
of the development of acute rejection while having highthree patients, and the dose was reduced in five patients.
Table 3 shows that in two patients (20 and 24), OKT3 therapeutic levels of CsA. In this patient, tacrolimus
was terminated with a successful resolution of TMA.was added to the regimen.
Two patients, 25 and 26 in Table 3, were on tacrolimus Unfortunately, this patient developed late-acute rejec-
tion 18 months later (40th month post-transplantation)at the time point when the biopsies showed TMA. We did
not attempt a conversion to CsA in these two patients; in and died from opportunistic infection while receiving
high-dose steroids.one patient, a simple dose reduction sufficed, and the
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Table 3. Renal graft recipients with TMA
Rejection TMA-onset
post-Tx post-Tx Follow-up
Patients Native renal SCr mg/dl Final SCr post-Tx
age, race, sex disease Graft days Treatment 1 year post-TMA mg/dl days Comments
1. 26 wm esrd-htn lrd I 2190 CsA→T 1.6 1.8 2252
2. 47 bf von hippel crt I 7 I 1460 CsA→T 1.5 1.7 2100
II 460
3. 40 wm dm k-p I 245 I 547 CsA→T 1.3 1.3 1200
4. 19 bf fsgs crt I 335 I 547 CsA→T 1.6 1.9 1020
5. 25 wm iddm k-p I 730 CsA→T 1.8 2.6 990
6. 37 wf esrd-htn lrd I 10 I 215 CsA→T 1.9 2.3 960 pheresis
7. 22 wm cong hypol crt I 120 I 7 CsA→T 1.9 2.7 870
II 90 T→discnt
8. 25 bm chr gn crt I 300 CsA→T 1.7 2.2 840
9. 36 wf chr gn lrd I 6 CsA→T 1.4 1.7 690
10. 38 bf iddm k-p I 23 I 240 CsA→T 1.2 1.1 630
II 45
11. 36 bf esrd-htn crt I 7 I 35 CsA→T 2.2 2.9 570
II 28
12. 35 wf pyelo crt I 30 I 540 CsA→T 2.4 dialysis 1140
II 390
13. 39 wf lupus lrd I 42 I 4 CsA→T 3.1 dialysis 960 CTN
14. 17 bm cong malf lrd I 730 I 1825 CsA→T dial dialysis 2005 pheresis,
II 1460 Tx nephct
15. 25 bf cresc gn crt I 540 I 450 CsA→T dial dialysis 510 lost 3 rej
16. 42 wm esrd-htn crt I 10 I 30 CsA→T dial dialysis 46 Tx nephct
17. 27 wf iddm lrd1p I 1185 CsA↓ 2.9 2.9 1950
18. 23 wf chr gn lrd I 510 CsA↓ 1.1 1.0 1380
19. 47 bm dm crt I 10 I 515 CsA↓ 2.6 dialysis 990 CTN
20. 18 bm nephr synd crt I 52 CsA↓1OKT3 dial dialysis 270
II 150 CsA no D
III 210 CsA→T
21. 41 wm chr gn crt I 340 CsA→discnt dial dialysis 570 CTN
22. 30 wf iddm k-p I 300 I 300 CsA→discnt 1.3 1.8 1230 Aza→mmf
23. 33 bf lupus crt I 5 I 10 CsA→discnt 1.0 1.3 510 Aza→mmf
II 26
24. 52 wf iddm k-p I 42 CsA↓1OKT3 2.0 2.1 240 died 3 stroke
25. 27 bm iddm k-p I 10 T no D 1.1 1.1 1110
26. 38 wf ANCA1gn lrd I 13 I 665 T→discnt 1.8 1.6 1210 late acute rej,
II 60 died 3 infect
III 120
Abbreviations are: b, African American; CTN, chronic transplant nephropathy; cong, congenital; crsc, crescentic; crt, cadaveric renal transplant; CsA, chclosporine;
dial, dialysis; discnt, discontinued; dm, diabetes mellitus; esrd, end-stage renal disease; f, female; fsgs, focal segmental glomerular sclerosis; gn, glomerulonephritis;
htn, hypertension; hypol, hypoplasia, iddm, insulin-dependent diabetes mellitus; infect, infection; lrd, living related donor; m, male; malf, malformation; nephct,
nephrectomy; nephr, nephrotic; pyelo, pyelonephritis; recur, recurrent; SCr, serum creatinine; syndr, syndrome; T, tacrolimus; Tx, transplant; uti, urinary tract infection;
w, Caucasian.
Of the total of 26 patients with TMA, 21 (81%) had tacrolimus in 5 and CsA in 19: Neoral in 17, Sandimmune
in 2, as shown in Figure 1. All but four patients were onfunctioning grafts with a mean serum creatinine of 1.78 6
0.13 mg/dl at the end of one year after the diagnosis of dihydropyridine calcium channel blocker. Graft function
loss was observed in 8 of the 24 patients.TMA. At the last follow-up, at 3.01 6 0.35 years, 18 of
26 (69%) patients had functioning grafts, with a mean Table 2 shows the findings in the 67 renal graft biopsies
from the 24 patients with renal graft dysfunction causedserum creatinine of 1.89 6 0.14 mg/dl.
by causes other than TMA. Arteriolar changes were less
Findings in patients without frequent in this group than in patients with previous
thrombotic microangiopathy episodes of TMA; cellular proliferation was seen in 26
of 67 (39%) and hyalinization in 8 of 67 (12%). TheClinical and pathological data from the 26 patients
with TMA were compared with clinical and pathological analysis of the 33 biopsies obtained during the first 90-
days post-transplantation showed foci of interstitial fi-findings in 24 patients with renal graft dysfunction caused
by other causes and to the clinical data of 19 patients brosis and tubular atrophy in seven (21%), and moderate
or severe rejection in seven (21%).with no renal graft dysfunction.
The therapy in the 24 patients with biopsy-proven Of the 19 patients who never had an episode of renal
graft dysfunction, all but three were on a dihydropyridinerenal graft dysfunction of non-TMA etiology included
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calcium channel blocker. One patient was on tacrolimus, when fibrin thrombi are observed in glomeruli and/or
arterioles [10, 17, 24]. The nonspecific fuchsinophilia of13 on Sandimmune, and 5 on Neoral, as shown in
Figure 1. All of these patients had an uneventful post- proteins on Masson’s trichrome facilitates the visualiza-
tion of the fibrin thrombus, as shown in Figure 2. Con-transplantation course and never required a graft biopsy.
The SCr was between 1.1 and 2.4 mg/dl (average of 1.53 6 firmation can be obtained by immunohistochemistry us-
ing antisera to fibrin. The diagnosis is evident when a0.11), up to 67 months after transplantation (average
3.2 6 0.4 years). large number of thrombi are present, but in cases with
scarce thrombi, careful scrutiny of all the sections is
essential in order to make the diagnosis. A statistically
DISCUSSION
significant finding in this series is the presence of cellular
Although the association between TMA and CsA is crescents in biopsies with TMA, as compared with biop-
well established, medical literature on CsA-associated sies from renal grafts with dysfunction of other etiology
TMA in renal allografts is not abundant. Our review (Table 2). In the biopsies with crescents, antibasement
demonstrated only three studies based on a series of membrane disease and antineutrophil cytoplasmic anti-
more than 10 patients [7, 21, 22]. Our series of 26 renal body-associated glomerulonephritis were ruled out by
graft recipients with TMA—24 patients with CsA-associ- serology, and immunoglobulin deposition was not ob-
ated TMA—possibly constitutes the largest study pub- served in the glomeruli. It is noteworthy that in older
lished to date. CsA-associated TMA is not exclusive to medical literature, crescents are included among the glo-
renal allografts. The medical literature documents CsA- merular findings in hemolytic uremic syndrome [25].
associated TMA in native kidneys of patients receiving As shown in Figure 1, the use of the microemulsion
CsA for the treatment of diseases such as uveitis and form of CsA, Neoral, was more frequent in TMA pa-
psoriasis [2, 5] and for nonrenal allografts [3, 9, 11, 13, tients than in patients with no graft dysfunction. Al-
15]. It has been estimated that the frequency of TMA though TMA was observed also in patients on tacrolimus
in bone marrow transplant recipients is between 6 and and Sandimmune, the use of Neoral was significantly
26% [23]. more frequent among the 26 TMA patients than among
The exact incidence of CsA-associated TMA in renal the 19 patients with no episodes of renal graft dysfunc-
graft recipients is not known, as renal biopsy is the only tion (P 5 0.0026). This finding raises the possibility that
available method of diagnosis of TMA, and indications Neoral, compared with the older preparation (Sandim-
for renal biopsy vary among medical centers. In this mune), is more likely to cause TMA. However, use of
series of renal allograft recipients treated over a three- Neoral was also more frequent among non-TMA graft
year period, TMA was diagnosed in 14% (26 of 188) of dysfunction patients. Therefore, it is difficult to make a
the patients, corresponding to 15% of the patients who definitive statement on the role of Neoral in contrast
had a renal graft biopsy (26 of 169). At Tulane Medical to Sandimmune. The advantages of the microemulsion
Center, renal graft biopsies are obtained for renal graft preparation (Neoral) over the older preparation (San-
dysfunction (a rise in serum creatinine of 0.5 mg/dl or dimmune) are increased bioavailability, more predict-
greater above baseline), and protocol biopsies are not able absorption, and therefore, easier dosing. On the
performed. The majority of our TMA patients, 24 of 26, other hand, the pharmacokinetic behavior of Neoral is
had an acute rise in serum creatinine of greater than 0.5 associated with generally rapid absorption with attain-
mg/dl above baseline without significant systemic symp- ment of higher peak drug levels in serum. It could be
toms. The post-transplantation time when TMA was di- proposed that this characteristic leads to an increase in
agnosed in our patients (from four days to six years) had the effects of CsA on the endothelium, possibly resulting
a wider range than has been previously described by in accentuated release of endothelin and other vasoactive
others [7]. products. Further understanding of the mechanisms in-
In this study, only 2 of the 26 patients with TMA had volved in the endothelial cell damage by CsA [22] is
systemic evidence of microangiopathy with decreased needed to develop scientific guidelines for therapeutic
platelet count, increased LDH and peripheral smear re- interventions.
vealing evidence of intravascular hemolysis. In the other We investigated other parameters that could contrib-
24 patients, there were no systemic clues to the diagnosis ute to TMA in our series. When patients with TMA and
of TMA, except for a rise in serum creatinine. These recipients with the best evolution, that is, with no episode
findings underscore the importance of considering TMA of renal graft dysfunction, were compared, the degree
in the differential diagnosis of patients with renal graft of donor/recipient HLA mismatch was not different in
dysfunction, even in the absence of systemic symptoms, the two groups. Furthermore, of the 35 recipients of
and of performing a renal allograft biopsy to confirm living-related donor grafts, eight patients had TMA, and
the diagnosis. another eight patients had no episodes of renal graft
dysfunction. In our series, TMA was observed in 7 of theCsA-associated TMA is diagnosed by renal biopsy
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39 patients who received kidney and pancreas allografts native kidneys from patients receiving CsA for nonrenal
allografts (solid organ grafts or bone marrow allografts)simultaneously, and in 19 out of 149 patients who re-
ceived a kidney-only allograft. This difference is not sta- clearly demonstrates that duplication of the glomerular
basement membrane and widening of the subendothelialtistically significant. An increased incidence of TMA in
kidney–pancreas graft recipients has been reported be- regions are frequent findings [3, 13–15]. These data are
consistent with the interpretation that in renal allografts,fore [21].
Although isometric vacuolization of the cytoplasm of these findings represent chronic CsA-effect and not re-
jection.the epithelium of the renal tubules, suggestive of acute
CsA toxicity, was twice as frequent in the biopsies taken In most studies of renal graft recipients, as in ours,
the occurrence of de novo TMA is associated with thefrom patients who later had TMA episodes than in biop-
sies from patients with other causes of renal graft dys- use of either CsA or tacrolimus. The exception is a series
of patients reported by Hourmant et al and reviewedfunction, this difference did not achieve statistical sig-
nificance. A review of the clinical charts shows that the by Colvin as acute idiopathic microangiopathy [26, 27].
Hourmant et al reviewed 1378 patients who receivedCsA dosage was moderate, approximately 5 to 12 mg/kg,
and no differences in CsA trough levels were observed renal allografts between 1979 and 1993 and observed
TMA in 17 [26]; the presentation of the TMA episodebetween the groups. The more frequent CsA tubular
toxicity in biopsies of patients who later developed TMA was during the first three post-transplantation months,
and none of the patients had TMA or hemolytic uremiccould be related to the rapid absorption and higher peak
drug levels of Neoral or represent an idiosyncratic pa- syndrome before transplantation. Of the 17 patients with
TMA, 13 were not on CsA at the time of the diagnosistient response to CsA.
Thrombotic microangiopathy can be observed in the of TMA. These findings are in distinct contrast to our
experience and that published by others, since all of ourcontext of vascular and of hyperacute rejection. Severe
rejection was not an important factor in our series, as TMA patients were on CsA or tacrolimus.
Our preferred therapy strategy for CsA-associatedsimultaneous TMA and moderate or severe rejection
was present in only 3 of 38 biopsies diagnostic of TMA. TMA, in 16 of the 24 patients, was conversion from CsA
to tacrolimus. The conversion strategy proved successfulInterstitial fibrosis and tubular atrophy in biopsies ob-
tained during the first 90 post-transplantation days possi- in 13 of 16 patients (81%) who had a well-functioning
graft one year after the TMA episode. Moreover, 11 ofbly reflects donor pathology. We observed this finding
more frequently in biopsies from patients with renal graft the 16 patients continued with a mean SCr of 1.9 6 0.14
mg/dl at their last check-up 3.01 6 0.3 years (mean 6dysfunction from causes different from TMA, consistent
with the interpretation that interstitial fibrosis of the sem) later. Controlled prospective clinical trials in renal
allograft recipients with TMA are needed to confirm thedonor kidney is not related to the induction of the TMA.
A frequently associated change in kidneys showing efficacy of CsA conversion to tacrolimus in other patient
populations. In view of the similarities between CsA andTMA on renal Bx, concentric proliferation of the cells of
the intima and the media, with deposition of intercellular tacrolimus, it is surprising that the conversion strategy
resulted in successful salvation of the grafts in a largematerial, is designated CsA arteriolopathy by some au-
thors [24]. CsA-associated arteriolopathy, with cell pro- fraction of our patients. Tacrolimus and CsA have similar
mechanisms of action and side effect profiles, and TMAliferation and hyalinization of the arteriolar walls, has
been described both in native kidneys of patients with can be associated with tacrolimus use, as seen in two of
our patients. In previous TMA series, graft failure wasnonrenal grafts and in renal allografts. In our series, the
increased incidence of arteriolopathy in 38 biopsies with observed in 5 of 14 patients (36%) [22] and in 12 of 21
(57%) patients [7]. In our series, the renal graft loss inTMA was statistically significant when compared with
the 67 biopsies of the 24 patients with other causes of patients with CsA-associated TMA with therapy switch
from CsA to tacrolimus was 19%.renal graft dysfunction (Table 2). In view of this observa-
tion, the search for fibrin thrombi is mandatory in biop- Young et al obtained a 92% graft survival using a
therapy regimen of pulse methylprednisolone and/or ansies with arteriolopathy. Considering the advantages of
CsA therapy, there is no consensus regarding recommen- antilymphocyte preparation in combination with isradi-
pine and an antiplatelet regimen of aspirin and pentoxi-dations for therapy modifications in patients with arte-
riolopathy without TMA on renal biopsy. fylline [21]. The difference between the experience re-
ported by these authors and our graft salvage successChronic transplant nephropathy [16], with interstitial
fibrosis, tubular atrophy, and thickened blood vessels, rate of 81% in patients switched from CsA to tacrolimus
is not statistically significant. It is noteworthy that basedwas twice as frequent in biopsies taken from patients
with prior episodes of TMA than in biopsies from pa- on serum creatinine levels, our cases appear to be milder
than those reported by Young et al. Moreover, mosttients with renal graft dysfunction of other etiology. The
medical literature on chronic CsA-associated TMA in of their patients had systemic signs of TMA, that is,
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significant reductions in platelet count and hematocrit patients, TMA was confined to the kidney with little
levels, in contrast to only 2 patients out of 26 in our or no systemic evidence of the thromboangiopathical
series. The reverse applies when we compare the biopsy process. Therefore, we recommend that any significant
findings: We observed cellular crescents in 9 of 38 biop- and persistent elevation in serum of creatinine, that is,
sies with TMA, whereas Young et al do not describe a greater than 0.5 mg/dl above baseline, be worked up
single such case. Whether the addition of aspirin and the with a graft biopsy. In our hands, the most successful
concomitant administration of either high-dose steroids intervention in patients with CsA-associated TMA was
or an antilymphocyte drug confers additional benefits conversion of CsA to tacrolimus, resulting in an 81%
cannot be ascertained from the comparison of these two one-year graft salvage.
series and requires a controlled prospective trial. It has
been suggested that complete regression of TMA can ACKNOWLEDGMENTS
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